Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine
β Scribed by Kenneth Miller; Gwen Abeles; Ruth Oratz; Anne Zeleniuch-Jacquotte; Jian Cui; Daniel F. Roses; Matthew N. Harris; Jean-Claude Bystryn
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 774 KB
- Volume
- 75
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
A critical requirement for cancer vaccines is that they stimulate CD8 Ψ T cell responses. In this study, we tested the ability of a polyvalent melanoma vaccine to induce CD8 Ψ T cell responses to the melanoma associated antigens MAGE-3 and Melan A/MART-1. Fifteen HLA-A2 Ψ patients with resected mali
## Abstract Simple, noninvasive methods are needed to follow effectiveness of new treatments in patients with melanoma. In our study, we examined cytoplasmic melanomaβassociated antigen (CYTβMAA) serum level in melanoma patients during immunotherapy. Sera of 117 patients were assayed for CYTβMAA by
A prediction of the theory of immunologic surveillance is that tumour antigens can be recognised by cell-mediated immunity during early development of the primary tumour by formation of tumour antigen-specific cytotoxic lymphocytes (CTLs) and that such recognition leads to destruction of those tumou
Human melanoma cells (from biopsies and culture) express sialyl-Lewis x and sialyl Lewis a , the ligands for ECAM. These ligands may facilitate tumor progression and metastasis in human cancers. To test whether the antibodies to these ligands inhibit tumor progression, IgG and IgM responses to sLe x